Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24047298 | 1.00 | ALB (0.41) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL25831639 | 1.00 | ALB (0.41) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL24047242 | 1.00 | ALB (0.41) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL26332859 | 0.88 | ALB (0.51) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL20729602 | 0.88 | ALB (0.51) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL24299247 | 0.88 | ALB (0.51) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL14194247 | 0.88 | ALB (0.51) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL24047299 | 0.76 | ALB (0.35) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL24047292 | 0.76 | ALB (0.35) | ALBLMNACYP2C9HTR2AADRA1A | |
| SCHEMBL25827337 | 0.76 | ALB (0.35) | ALBLMNACYP2C9HTR2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203081-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203081-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | NPEPPS, TLR7, ASNS | ALB 1451/4885LMNA 218/4885CYP2C9 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.